64: Genetics, Advocacy, and Big Data in ALS

NeurologyLive® Mind Moments®

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Matthew B. Harms, MD, associate professor of neurology, Columbia University, and medical consultant and care center director, Muscular Dystrophy Association (MDA). He spoke about the progress that the field has seen in recent years in improving the genetic understanding of amyotrophic lateral sclerosis (ALS) and the role that big data can play in care, as well as shared his perspective on the impact that advocacy efforts have had on these advances.

Episode Breakdown:

• 2:05 – Major progress in ALS in recent years
• 4:35 – Key steps forward in genetic testing
• 7:25 – The understanding of genetics in ALS
• 9:20 – The role of databases in the care paradigm
• 11:35 – Neurology News Minute
• 15:25 – Advocacy's role in the last decade
• 18:40 – The state of clinical trials for ALS
• 20:40 – The pipeline of therapies and the future of treatment
• 24:50 – Importance of continued advocacy for ALS

Check out Medical World News' Second Opinion only at medicalworldnews.com
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• National Institutes of Health Launches Phase 1 Trial to Study Epstein-Barr Virus Vaccine
• Eisai Completes Rolling BLA Submission for Lecanemab to Treat MCI, Alzheimer Disease
• FDA Approves Oral Version of Edaravone for ALS

Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.